Royalty Report: Drugs, Cancer, Disease – Collection: 279359


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • cell therapy

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 279359

License Grant
The Japanese Licensor grants an exclusive, even as to Licensor, right and license, with the right to grant sublicenses, in the field in the territory under Licensor Patent and Licensor Technical information to make, have made, develop, have developed, import, have imported, export, have exported, use, have used, offer to sell, sell, and have sold the Compound and/or the Product.
License Property
Licensor is the proprietor of certain patents and patent applications relating to the Compound and possesses technical information relating to the same.

Product shall mean any pharmaceutical preparation suitable for administration for human use containing the Compound as an active ingredient.

Compound shall mean the chemical compound [N-[3-(4,5-bipyrimidin-2-ylamino)-4-methylphenyl)-4-
{ [ (3S )-3-( dimethylamino) pyrrolidin- 1-yl) methyl}-3-(trifluoromethyl) benzamide], of which code name is designated as __-187.

Field of Use
NS-187 is an orally bioavailable, rationally designed, dual Bcr-Abl and Lyn kinase inhibitor. Bcr-Abl is commonly recognized as the primary molecular target in the treatment of CML.
Chronic myelogenous leukemia (CML) is a cancer that affects your blood cells and bone marrow — the soft part inside your bones where blood cells are made.

IPSCIO Record ID: 369259

License Grant
Licensor grants an exclusive, non-transferable right and license under Licensor Know-How and Patents, with the right, to grant sublicenses through multiple tiers of Sublicensees, to research, Develop, make, have made, import, export, use, sell, offer for sale, have sold and otherwise Commercialize Licensed Products in the Licensed Field in the Licensed Territory.

Licensor does grant a non-exclusive license to use the Licensor Trademarks.

License Property
Licensor is developing pacritinib and has the rights to related patents and technology.

Pacritinib Citrate means the citrate salt of 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene.

The trademarks are CTI and other Licensor owned trademarks.

Pacritinib is a macrocyclic Janus kinase inhibitor that is being developed for the treatment of myelofibrosis.

Field of Use
Pacritinib is a novel investigational JAK2/FLT3 inhibitor with activity against genetic mutations linked to myelofibrosis, leukemia and certain solid tumors. Pacritinib is currently in Phase III development for patients with myelofibrosis, a chronic malignant bone marrow disorder.

The Licensed Field means all human therapeutic indications.  The Initial Indication means Myelofibrosis.

Myelofibrosis is an uncommon type of bone marrow cancer that disrupts your body's normal production of blood cells. Myelofibrosis causes extensive scarring in your bone marrow, leading to severe anemia that can cause weakness and fatigue.

IPSCIO Record ID: 245935

License Grant
Licensor hereby grants to Swiss Licensee and its Affiliates an exclusive, non-transferable (except as expressly authorized in this Agreement), royalty-bearing license, with the right to sublicense as qualified, under the Licensed Patents, Licensed Products Improvements to the extent Controlled by Licensor, and Licensed Know-How to use, develop, import, offer for sale, have sold and sell, the Licensed Products in the Territory, and a non-exclusive license thereunder to make and have made the Licensed Products worldwide, for all diagnostic, preventive and therapeutic uses in the human diseases Myelodysplastic Syndromes (“MDS”) Acute Myelogenous Leukemia (“AML”) and any other indications or uses (the “Field”).  Licensor also hereby grants Licensee a license to use the Dacogen Trademark as provided in this Agreement. Licensor reserves all rights not expressly granted herein, and no other rights shall be considered granted by Licensor by implication, estoppel, reliance, or otherwise. Notwithstanding anything to the contrary, no rights or licenses are granted by Licensor in this Agreement with respect to any active ingredient other than Decitabine or with respect to any product other than the Licensed Products.
License Property
Licensed Patents
6,613,753 – Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
6,982,253 – Liquid formulation of decitabine and use of the same
6,998,391 – Method for treating diseases associated with abnormal kinase activity
6,905,669 – Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase

DACOGEN Trademark shall me mean the DACOGEN mark and accompanying logos associated with it.

Products shall mean (i) the product containing Decitabine which is the subject of Licensor’s NDA No. 21-790 as of the date of signing of this Agreement; and (ii) any other pharmaceutical product containing as an active ingredient Decitabine.

Decitabine shall mean the compound identified below, and all stereoisomers, salts and polymorphs of the compound identified below. Esters and acids of the compound identified below shall be included to the extent they constitute the same active ingredient as the compound identified below.

Exact Mass 228.086
Mol. Wt. 228.205

Field of Use
The Field shall mean preventive and therapeutic uses in the human diseases Myelodysplastic Syndromes (“MDS”) Acute Myelogenous Leukemia (“AML”) and any other indications or uses.

Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.

IPSCIO Record ID: 280934

License Grant
This agreement is for development and commercialization of the clinical compound forodesine hydrochloride in markets across Europe, Asia and Australasia.

Licensor grants the Licensee of Bermuda an exclusive right and license in the Territory, with the right to sublicense, to Develop, make, have made, package and have packaged, use, promote, market, offer for sale, sell and import Licensed Products in the Field, under the Licensor Patents, Licensor Know-How and the Trademark.

Licensor grants during the Term of this Agreement a limited non-exclusive right to use the Licensor Logo on Promotional Literature in the Field in the Territory.

License Property
Licensor owns or controls patents and know-how related to a series of proprietary compounds which act as PNP Inhibitors, including the compound known as __X-1777.

Licensed Products means all pharmaceutical preparations in all dosage strengths, formulations and methods of administration that contain the Compound as its active ingredient, alone or in combination with another active ingredient.

Trademark means the trademark Fodosine or such other trademark approved by the JDC for use in connection with the Licensed Products, but excluding the Secondary Marks.

B-cell Acute Lymphoblastic Leukemia/lymphoma or B-ALL means a disease in which certain cells of the B lymphocytes or B-cells are malignant, and have populated the bone marrow.

B-CLL means B-type chronic lymphocytic leukemia.

B-NHL means a Non-Hodgkin’s lymphoma in which the malignant cells have characteristics predominantly of the B lineage.

Field of Use
Field means the treatment of all Cancerous and/or Pre-Cancerous States in humans, specifically for the treatment of certain T-cell and B-cell mediated diseases in the area of oncology.
Fodosineâ„¢ is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is currently being studied in a number of clinical trials including a Phase IIa clinical trial in patients with T-cell leukemia.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.